BR112018075140A2 - composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8 - Google Patents
composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8Info
- Publication number
- BR112018075140A2 BR112018075140A2 BR112018075140-5A BR112018075140A BR112018075140A2 BR 112018075140 A2 BR112018075140 A2 BR 112018075140A2 BR 112018075140 A BR112018075140 A BR 112018075140A BR 112018075140 A2 BR112018075140 A2 BR 112018075140A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- aqueous solution
- single dose
- injectable aqueous
- dose formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
resumo "composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8"
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1655222A FR3052072A1 (fr) | 2016-06-07 | 2016-06-07 | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
FR1655222 | 2016-06-07 | ||
PCT/EP2017/063886 WO2017211916A1 (fr) | 2016-06-07 | 2017-06-07 | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, une insuline prandiale et/ou une hormone gastrointestinale, et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018075140A2 true BR112018075140A2 (pt) | 2019-03-26 |
Family
ID=57348773
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018075140-5A BR112018075140A2 (pt) | 2016-06-07 | 2017-06-07 | composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8 |
BR112018075151-0A BR112018075151A2 (pt) | 2016-06-07 | 2017-06-07 | composição na forma de uma solução aquosa injetável, cujo ph é de 6,0 a 8,0 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018075151-0A BR112018075151A2 (pt) | 2016-06-07 | 2017-06-07 | composição na forma de uma solução aquosa injetável, cujo ph é de 6,0 a 8,0 |
Country Status (12)
Country | Link |
---|---|
US (2) | US10383920B2 (pt) |
EP (2) | EP3463293B1 (pt) |
JP (1) | JP2019517555A (pt) |
CN (2) | CN109379888B (pt) |
BR (2) | BR112018075140A2 (pt) |
EA (2) | EA039363B1 (pt) |
FR (1) | FR3052072A1 (pt) |
MX (2) | MX2018015068A (pt) |
PH (1) | PH12018502558A1 (pt) |
SA (2) | SA518400588B1 (pt) |
SG (2) | SG11201810935SA (pt) |
WO (2) | WO2017211916A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3070264A1 (fr) * | 2017-08-24 | 2019-03-01 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
FR3083089A1 (fr) * | 2018-06-29 | 2020-01-03 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
FR3083086A1 (fr) * | 2018-06-29 | 2020-01-03 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
JP2021505607A (ja) | 2017-12-07 | 2021-02-18 | アドシア | 5.8〜8.5のpIを有する少なくとも1つの基礎インスリンならびにカルボキシレート電荷および疎水性ラジカルを有するコポリアミノ酸を含むpH7の注射溶液 |
WO2019110797A1 (fr) * | 2017-12-07 | 2019-06-13 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
JP2021505616A (ja) | 2017-12-07 | 2021-02-18 | アドシア | アミリン、アミリンアゴニスト受容体またはアミリン類似体およびコポリアミノ酸を含む注射水溶液の形態の組成物 |
CN111836616B (zh) | 2017-12-07 | 2024-01-16 | 阿道恰公司 | 包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的ph 7为7的可注射溶液 |
WO2019110773A1 (fr) | 2017-12-07 | 2019-06-13 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
WO2019115411A1 (fr) * | 2017-12-07 | 2019-06-20 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
FR3067247A1 (fr) * | 2018-06-07 | 2018-12-14 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide |
WO2019243628A1 (fr) * | 2018-06-22 | 2019-12-26 | Adocia | Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal |
FR3084585B1 (fr) * | 2018-08-03 | 2020-11-06 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un compose amphiphile porteur de radicaux hydrophobes |
FR3084586B1 (fr) * | 2018-08-03 | 2020-11-06 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes |
WO2020115334A1 (fr) * | 2018-12-07 | 2020-06-11 | Adocia | Procede de preparation d'une composition stable sous forme d'une solution aqueuse injectable |
US20200179489A1 (en) * | 2018-12-07 | 2020-06-11 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol |
WO2020245470A1 (fr) | 2019-06-07 | 2020-12-10 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, du liraglutide et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3482551D1 (de) | 1983-10-26 | 1990-07-26 | Kanebo Ltd | Proteinhaltiges emulgiermittel, dessen herstellung und dieses enthaltende emulgierte kosmetische zusammensetzung. |
DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
FR2801226B1 (fr) | 1999-11-23 | 2002-01-25 | Flamel Tech Sa | Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation |
CZ2004710A3 (cs) | 2001-12-20 | 2005-02-16 | Eli Lilly And Company | Inzulínová sloučenina s protrahovaným účinkem |
FR2840614B1 (fr) | 2002-06-07 | 2004-08-27 | Flamel Tech Sa | Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques |
BRPI0409600A (pt) | 2003-04-29 | 2006-04-18 | Lilly Co Eli | análogo de insulina, composição, método de tratamento de hiperglicemia, e, análogo de pró-insulina |
FR2862535B1 (fr) * | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee d'interleukines et leurs applications therapeutiques |
FR2915683B1 (fr) * | 2007-05-03 | 2009-08-07 | Flamel Technologies Sa | Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif |
CA2843586A1 (fr) * | 2011-08-10 | 2013-02-14 | Adocia | Solution injectable d'au moins une insuline basale |
FR2985429B1 (fr) | 2012-01-09 | 2016-07-29 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle |
CN104114155B (zh) * | 2012-01-09 | 2019-02-15 | 阿道恰公司 | Ph为7并且至少包含pi为5.8至8.5之基础胰岛素和经取代共聚(氨基酸)的可注射溶液 |
FR3001896B1 (fr) | 2013-02-12 | 2015-07-03 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise |
FR3001895B1 (fr) | 2013-02-12 | 2015-07-03 | Adocia | Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes |
-
2016
- 2016-06-07 FR FR1655222A patent/FR3052072A1/fr not_active Withdrawn
-
2017
- 2017-06-07 US US15/616,128 patent/US10383920B2/en active Active
- 2017-06-07 WO PCT/EP2017/063886 patent/WO2017211916A1/fr unknown
- 2017-06-07 EA EA201892737A patent/EA039363B1/ru unknown
- 2017-06-07 EA EA201892736A patent/EA039333B1/ru unknown
- 2017-06-07 MX MX2018015068A patent/MX2018015068A/es unknown
- 2017-06-07 WO PCT/EP2017/063865 patent/WO2017211903A1/fr unknown
- 2017-06-07 MX MX2018015067A patent/MX2018015067A/es unknown
- 2017-06-07 BR BR112018075140-5A patent/BR112018075140A2/pt not_active Application Discontinuation
- 2017-06-07 SG SG11201810935SA patent/SG11201810935SA/en unknown
- 2017-06-07 US US15/616,470 patent/US10548952B2/en active Active
- 2017-06-07 BR BR112018075151-0A patent/BR112018075151A2/pt not_active Application Discontinuation
- 2017-06-07 CN CN201780035320.2A patent/CN109379888B/zh active Active
- 2017-06-07 SG SG11201810937WA patent/SG11201810937WA/en unknown
- 2017-06-07 JP JP2018564355A patent/JP2019517555A/ja active Pending
- 2017-06-07 CN CN201780047889.0A patent/CN109640953B/zh active Active
- 2017-06-07 EP EP17727910.6A patent/EP3463293B1/fr active Active
- 2017-06-07 EP EP17727906.4A patent/EP3463292B1/fr active Active
-
2018
- 2018-12-04 SA SA518400588A patent/SA518400588B1/ar unknown
- 2018-12-04 PH PH12018502558A patent/PH12018502558A1/en unknown
- 2018-12-05 SA SA518400596A patent/SA518400596B1/ar unknown
Also Published As
Publication number | Publication date |
---|---|
JP2019517555A (ja) | 2019-06-24 |
US10383920B2 (en) | 2019-08-20 |
US20170348423A1 (en) | 2017-12-07 |
US20170348396A1 (en) | 2017-12-07 |
EP3463292B1 (fr) | 2020-08-05 |
SG11201810937WA (en) | 2019-01-30 |
MX2018015068A (es) | 2019-05-09 |
SA518400596B1 (ar) | 2022-03-16 |
CN109640953A (zh) | 2019-04-16 |
EP3463293A1 (fr) | 2019-04-10 |
BR112018075151A2 (pt) | 2019-03-26 |
PH12018502558A1 (en) | 2019-10-14 |
CN109379888B (zh) | 2021-10-29 |
FR3052072A1 (fr) | 2017-12-08 |
EA201892736A1 (ru) | 2019-05-31 |
CN109640953B (zh) | 2021-10-29 |
EA201892737A1 (ru) | 2019-05-31 |
SG11201810935SA (en) | 2019-01-30 |
MX2018015067A (es) | 2019-05-09 |
SA518400588B1 (ar) | 2022-03-07 |
WO2017211903A1 (fr) | 2017-12-14 |
US10548952B2 (en) | 2020-02-04 |
EP3463292A1 (fr) | 2019-04-10 |
EP3463293B1 (fr) | 2021-05-12 |
WO2017211916A1 (fr) | 2017-12-14 |
EA039333B1 (ru) | 2022-01-14 |
EA039363B1 (ru) | 2022-01-18 |
CN109379888A (zh) | 2019-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018075140A2 (pt) | composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8 | |
BR112018075250A2 (pt) | composição na forma de uma solução aquosa injetável, cujo ph é de 6,0 a 8,0 | |
CO2017005995A2 (es) | Composiciones para el cuidado bucal y métodos de uso | |
BR112014016889A8 (pt) | composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8 | |
DOP2016000298A (es) | Pirazolopiridinas y pirazolopirimidinas | |
EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
BR112018010211A2 (pt) | formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab | |
CL2016001120A1 (es) | Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct | |
CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
CL2015002860A1 (es) | Antagonistas de la alfa-v-beta-6 integrina | |
EA201591004A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
BR112015022782A2 (pt) | composto, composição farmacêutica, combinação, e, uso de um composto | |
CR20170425A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
BR112017000313A2 (pt) | sistema para o fornecimento de uma composição para tratamento bucal, composição para tratamento bucal, método para administrar uma composição para tratamento bucal | |
AR098168A1 (es) | Formulación estable de insulina glulisina | |
EA202191513A1 (ru) | Снижение вязкости фармацевтических составов | |
BR112016022394A2 (pt) | Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável | |
WO2014153009A3 (en) | Thiosaccharide mucolytic agents | |
BR112017008481A2 (pt) | composto antimicótico | |
PE20160012A1 (es) | Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral | |
DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
CL2016000019A1 (es) | Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión. | |
AR101581A1 (es) | Composición de colutorio | |
CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |